Recognition of the ability of D4R expression and PLM activation to modulate MS activity, GSH levels, the SAM/SAH ratio, and DNA methylation has potential implications for the clinical management of schizophrenia, ADHD, autism, and other neuropsychiatric disorders. This evidence concerns the gene FXYD1 and schizophrenia.